Arikayce™

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	3

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01315678 (ClinicalTrials.gov)	February 29, 2012	14/3/2011	Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections	Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tole ...	Pseudomonas Aeruginosa Infection	Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. ...	Insmed Incorporated	NULL	Completed	6 Years	N/A	All	302	Phase 3	Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Pola ...
2	NCT03905642 (ClinicalTrials.gov)	January 8, 2009	2/4/2019	Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase	Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARI ...	Cystic Fibrosis	Drug: Arikayce™	Insmed Incorporated	NULL	Completed	6 Years	N/A	All	49	Phase 2	Belgium;Hungary;North Macedonia;Poland;Serbia;Slovakia;Ukraine;Macedonia, The Former Yugoslav Republ ...
3	NCT00558844 (ClinicalTrials.gov)	January 2008	13/11/2007	Safety/Tolerability Study of Arikayce™in Cystic Fibrosis Patients With Chronic Infection Due to Pseu ...	Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) ...	Cystic Fibrosis	Drug: Arikayce™560 mg;Drug: Placebo for 560 mg;Drug: Arikayce™70 mg;Drug: Arikayce™140 mg;Drug: Plac ...	Insmed Incorporated	NULL	Completed	6 Years	N/A	All	41	Phase 1/Phase 2	United States

First Previous1Next Last